Expert Outlook: Intellia Therapeutics Through The Eyes Of 7 Analysts
Expert Outlook: Intellia Therapeutics Through The Eyes Of 7 Analysts
專家視角：通過7位分析師的眼睛看Intellia Therapeutics
During the last three months, 7 analysts shared their evaluations of Intellia Therapeutics (NASDAQ:NTLA), revealing diverse outlooks from bullish to bearish.
在過去的三個月中，7位分析師分享了他們對Intellia Therapeutics（納斯達克股票代碼：NTLA）的評估，揭示了從看漲到看跌的不同前景。
The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.
下表簡要概述了分析師最近的評級，提供了對過去30天情緒變化的見解，並與前幾個月進行了比較以獲得整體視角。
In the assessment of 12-month price targets, analysts unveil insights for Intellia Therapeutics, presenting an average target of $70.86, a high estimate of $120.00, and a low estimate of $54.00. A 5.34% drop is evident in the current average compared to the previous average price target of $74.86.
在評估12個月目標股價時，分析師公佈了對Intellia Therapeutics的見解，將平均目標股價定爲70.86美元，最高估計爲120.00美元，低估值爲54.00美元。與之前的平均目標股價74.86美元相比，當前的平均價格下降了5.34％。
Exploring Analyst Ratings...
探索分...
登入免費觀看全文
登入/註冊
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。